Et fase 1, dosis-eskaleringsstudie af [225Ac]-FPI-2068 i voksne patienter med avancerede solide tumorer
Et fase 1, første-i-menneske, multicenter, åbent, dosiseskaleringsstudie af [225Ac]-FPI-2068 i voksne patienter med avancerede solide tumorer
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The study will be conducted in 2 parts:
Part A: optimization of the FPI-2053 dose (treatment with dose level 1 of [225Ac]-FPI-2068 - fixed dose).
Part B: dose escalation of [225Ac]-FPI-2068 with optimal FPI-2053. Part B will commence once the optimal dose of FPI-2053 is determined in Part A. The RP2D will be determined from Part B based on all available safety, efficacy, PK, and dosimetry information.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Research Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Site
-
-
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Research Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68130
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Research Site
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Research Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
Histologically and/or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent or inoperable.
Disease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the participant refuses standard therapy.
Measurable disease as defined by RECIST Version 1.1
ECOG Performance status of 0 or 1
Adequate organ function
Key Exclusion Criteria:
Previous treatment with any systemic radiopharmaceutical
Prior anti-cancer therapy unless adequate washout and recovery from toxicities
Contraindications to or inability to perform the imaging procedures required in this study
Radiation therapy (RT) within 28 days prior to the first dose of [111In]-FPI-2107
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (≥ once per month)
Patients with known CNS metastatic disease unless treated and stable
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dose Exploration and Dose Escalation
The study conducted in two parts: Part A Dose Exploration and Part B Dose Escalation FPI-2053 dose exploration to determine the optimal pre-dose administration of FPI-2053 with a fixed dose of [225Ac]-FPI-2068. [225Ac]-FPI-2068 dose escalation with the optimal dose of FPI-2053 as determined in Part A. |
FPI-2053 is a bispecific antibody that targets EGFR and cMET [111In]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053. Participants will have a fixed dose of [111In]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053). [225Ac]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053. Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068
Tidsramme: From informed consent up to approximately 5 years post last administration
|
Frequency, duration, and severity of AEs, DLTs, and changes in clinical, laboratory, and ECG parameters compared to baseline |
From informed consent up to approximately 5 years post last administration
|
|
Determine radiation dose of [111In]-FPI-2107 and [225Ac]-FPI-2068 to whole body, organs, and selected regions of interest.
Tidsramme: Within 56 days of administration
|
Changes in uptake of [111In]-FPI-2107 and projected RAD of [225Ac]-FPI-2068 by imaging following the administration of varying doses of FPI-2053 |
Within 56 days of administration
|
|
Determine the RP2D of [225Ac]-FPI-2068, given with or without FPI-2053
Tidsramme: 56 days post administration
|
Estimates of residence time and absorbed radiation doses to the whole body, organs, and selected regions of interest for [111In]-FPI-2107 and [225Ac]-FPI-2068. |
56 days post administration
|
|
Determine the effect of predose administration of varying doses of FPI-2053 on the radiation dosimetry of [111In]-FPI-2107 and [225Ac]-FPI-2068 to whole body, organs, and selected regions of interest.
Tidsramme: 56 days post-administration
|
Changes in uptake of [111In]-FPI- 2107 and projected RAD of [225Ac]-FPI-2068 by imaging following the administration of varying doses of FPI-2053 |
56 days post-administration
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess preliminary anti-tumor activity of [225Ac]-FPI-2068
Tidsramme: Approximately 5 years post final administration
|
|
Approximately 5 years post final administration
|
|
Tumor uptake of [111In]-FPI-2107
Tidsramme: Within 56 days of administration
|
• Tumor uptake of [111In]-FPI-2107 in selected regions of interest on SPECT/CT and/or planar images |
Within 56 days of administration
|
|
Pharmacokinetics (PK) of [111In]-FPI-2107, and [225Ac]-FPI-2068, by measuring changes in clearance, AUC, Cmax, and half-life.
Tidsramme: From first dose of investigation product until 56 days after the last dose of investigational product.
|
• Determine the plasma concentrations and PK parameters of [111In]-FPI-2107, and [225Ac]-FPI-2068 and the effect of pre-dose administration of FPI-2053 on the plasma concentrations and PK parameters of [111In]-FPI-2107. |
From first dose of investigation product until 56 days after the last dose of investigational product.
|
|
To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053
Tidsramme: From first dose of investigation product until 56 days after the last dose of investigational product.
|
• Presence of ADA for [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053 |
From first dose of investigation product until 56 days after the last dose of investigational product.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Monoklonalt antistof
- NSCLC
- Faste tumorer
- EGFR
- HNSCC
- Radioligand terapi
- RLT
- cMET
- PDAC
- Epidermal vækstfaktor receptor
- Bispecifikt antistof
- mCRC
- RCC
- EGFRm
- Actinium-225
- GC
- EGFRwt
- 225Ac
- Målrettet alfaterapi
- TAT
- Mesenkymal-epitelial overgangsfaktor
- FPI-2068
- FPI-2107
- FPI-2053
- Indium-111
- 111In
- Radioimmuno-SPECT-middel
- Radioimmuno-terapeutisk middel
- Bifunktionelt chelateringsmiddel
- Radiofarmaceutisk terapi
- Alfa partikel emitter
- Styret bispecifikt monovalent antistof
- bsAb
- Bifunktionelt chelat
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Lungesygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Lungeneoplasmer
- Urologiske neoplasmer
- Karcinom
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Karcinom, pladecelle
- Planocellulært karcinom i hoved og hals
- Neoplasmer i maven
- Kolorektale neoplasmer
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- FPI-2068-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .